CORDIS
EU research results

CORDIS

English EN

European Screening Centre; Unique Library for Attractive Biology

Project information

Grant agreement ID: 806948

Status

Ongoing project

  • Start date

    1 December 2018

  • End date

    30 November 2023

Funded under:

H2020-EU.3.1.7.

  • Overall budget:

    € 36 729 319,50

  • EU contribution

    € 18 249 992,50

Coordinated by:

STICHTING LYGATURE

Netherlands

Objective

By bridging an important gap between basic research and drug development, ESCulab will facilitate the translation of fundamental scientific insights into innovative drug starting points. New biological ideas will be collected by crowdsourcing, novel targets, phenotypes and pathways translated and de-risked by delivering high-quality chemical starting points for drug development. Innovators from EU academics and SMEs are offered access to state-of-the-art industry-grade facilities, drug discovery expertise, and a top-quality, curated library with over 550,000 unique compounds suitable for screening potential drug targets. The ESCulab drug discovery data generated will allow the innovators to build a proposition that is likely to attract investors and/or drug developers and stimulate them to further exploit these findings. Ultimately, this will result in novel medicines – based on basic scientific findings – that will help patients (sooner).

ESCulab will achieve this by starting off the shoulders of the European Lead Factory (ELF), where this principle has been successfully implemented. 15 out of the 18 ESCulab consortium members were involved in ELF, thus ensuring maximum benefit from the ELF legacy. ESCulab will expand and enhance ELF by supporting 185 new screens. Important additions include the application of a much larger compound collection for screening, the ability to accommodate the more complex phenotypic screening assays, and the building of a sustainable business model to ensure access to Collaborative Drug Discovery activities beyond the funding period. The delivery of qualified hit lists (QHLs) is the end point for this project, but during the funding period, ESCulab will attract additonal funding for externally paid screens and hit-to-lead projects for organizations such as charities and foundations for long term sustainability of the initiative.

Coordinator

STICHTING LYGATURE

Address

Jaarbeursplein 6
3521 Al Utrecht

Netherlands

Activity type

Other

EU Contribution

€ 1 434 943,75

Participants (19)

PIVOT PARK SCREENING CENTRE BV

Netherlands

EU Contribution

€ 7 128 756,25

BIOASCENT DISCOVERY LIMITED

United Kingdom

EU Contribution

€ 6 475 450

TAROS CHEMICALS GMBH & CO KG

Germany

EU Contribution

€ 292 600

THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF OXFORD

United Kingdom

EU Contribution

€ 491 230

EDELRIS SAS

France

EU Contribution

€ 292 600

SYGNATURE DISCOVERY LIMITED

United Kingdom

EU Contribution

€ 292 600

SYNCOM BV

Netherlands

EU Contribution

€ 292 600

UNIVERSITY OF DUNDEE

United Kingdom

EU Contribution

€ 1 256 612,50

BAYER AKTIENGESELLSCHAFT

Germany

ASTRAZENECA AB

Sweden

GRUNENTHAL GMBH

Germany

JANSSEN PHARMACEUTICA NV

Belgium

MERCK KOMMANDITGESELLSCHAFT AUF AKTIEN

Germany

SANOFI-AVENTIS DEUTSCHLAND GMBH

Germany

INSTITUT DE RECHERCHES SERVIER

France

UCB BIOPHARMA SRL

Belgium

Medicines for Malaria Venture

Switzerland

MERCATORIAL BV

Netherlands

EU Contribution

€ 265 243,75

MERCALEADS BV

Netherlands

EU Contribution

€ 27 356,25

Project information

Grant agreement ID: 806948

Status

Ongoing project

  • Start date

    1 December 2018

  • End date

    30 November 2023

Funded under:

H2020-EU.3.1.7.

  • Overall budget:

    € 36 729 319,50

  • EU contribution

    € 18 249 992,50

Coordinated by:

STICHTING LYGATURE

Netherlands